Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
about
Transhiatal esophagectomy in a high volume institutionPreoperative chemotherapy for resectable thoracic esophageal cancerPreoperative chemotherapy for resectable thoracic esophageal cancerNeoadjuvant therapy for gastroesophageal adenocarcinomaEmerging therapeutic targets in esophageal adenocarcinomaPerioperative and Palliative Chemotherapy for Esophageal CancerUnderstanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and SurvivalRadiation therapy and esophageal cancerThe role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tractAdvances in Radiotherapy Management of Esophageal CancerReevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 YearsLocally advanced gastroesophageal junction tumor: a treatment dilemmaComparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differencesSystematic review of patient-reported outcome measures in the surgical treatment of patients with esophageal cancer.Preoperative chemoradiotherapy for esophageal cancer: impressive downstaging with acceptable toxicity.Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junctionProspective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer.Exocrine pancreatic insufficiency following esophagectomy.Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer.The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy.Minimally invasive surgery and cancer: controversies part 1.Radio(chemo)therapy in Elderly Patients with Esophageal Cancer: A Feasible Treatment with an Outcome Consistent with Younger Patients.Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matched study.Sleep disturbances and quality of life in postoperative management after esophagectomy for esophageal cancer.Current management of esophageal cancerDoes the timing of esophagectomy after chemoradiation affect outcome?The Feasibility of (18)F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer.High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma.Traditional invasive vs. minimally invasive esophagectomy: a multi-center, randomized trial (TIME-trial).Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective studyNeoadjuvant chemoradiotherapy for esophageal cancer: impact on extracapsular lymph node involvement.Current strategies in chemoradiation for esophageal cancer.CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamouEsophageal adenocarcinoma: treatment modalities in the era of targeted therapy.Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.Predicting response to neoadjuvant therapy in esophageal cancer.Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
P2860
Q21093263-044B4E19-1C3A-43C5-BDAB-83F7D29DB5A5Q24187910-F45D99E0-E6F2-46D5-8967-69AA8935B850Q24245213-52D3C6A1-DB30-4D6E-9519-771EF6C812D1Q26746147-3933337C-DE84-4746-BF71-8AA7CE1DF960Q26751209-188BB01A-FA6D-4C96-820D-471584894132Q26753865-0E4CE0E3-CB87-49C6-BD61-FAA0256EA257Q26798220-E7A17264-F09D-48EC-877E-463D0285BB47Q27026922-8307E65C-B40F-4608-99F1-007AEC3E57DBQ27687612-70899C7C-4EF6-45E3-96B8-4B58B7E4422AQ28078750-2BB0CE92-CF1D-4D88-91FB-885C68974E99Q28081365-B39CFC6E-BE8B-4885-8DB0-883F457244D2Q28082596-0FB64EE4-FCF2-40B4-853E-ABAAE833C134Q28086772-AF2F1C8F-2FF7-4BC3-A989-D7BD056E6CE6Q30252079-E5B81F1C-482A-4011-8535-1703BC3BF214Q30440098-C75ACBFE-C890-461A-B31E-B337AC84EF5EQ30537735-959904C9-CD58-42B2-AFDF-311B8050E3EDQ30907567-9B3A6655-D4DC-4D07-8402-663CD8732676Q33356751-99AC8F3B-A244-449C-AF64-712B3B73BC63Q33387427-CF391CCB-58A6-434E-9657-CE370EDBA582Q33400021-6CCDB1EC-5695-4071-AAAF-192C6059DB02Q33456528-B44A3030-B7C2-4704-8F00-736A5F28E5A9Q33587884-11F60D26-8BEA-4458-B3D3-DF91E75FBFE7Q33592961-C3F20F1E-E2A5-4A4A-8B65-485C7306CDA0Q33622016-C13634CE-DF9B-49CD-AF29-27BF92FE943BQ33633972-688E0154-2E84-4025-A974-FA80F60044ABQ33653046-9132A7EF-FD40-4923-B3ED-74B062F38773Q33655261-C7659C2F-354D-4033-AD5A-74FAF0439766Q33658207-23D8D257-C067-4D52-A555-6B3D8DCFAFE4Q33699376-20C4709F-EC9B-4038-864C-DF4DF40FBB81Q33704276-11AFD718-E481-4DB6-B3DF-9C96EFCBEA36Q33739931-0C20A553-B3A4-45B4-BAD4-44A6B0D7D787Q33791252-1585B762-7542-4A00-94C6-0BCA943E8ABDQ33795763-8F1CD00F-6D62-4051-AF08-205DB5AA4407Q33812166-0C3B9B9E-BEB1-4705-863F-32A49766F2B3Q33820782-64A3F827-D596-4ED5-BB67-ADD043293049Q33850915-A02A31F1-DBB8-4D12-9A85-D2A658B5082AQ33932460-A629844B-60D4-492A-AB2F-A9879EF756C3Q33942343-BB47B0FC-EA64-4943-B289-48723E1908BEQ34022135-73959420-2AF1-474A-A757-822E0883B6D1Q34039184-7CF90AB9-6089-4AF8-BD50-893E1EDFD9DD
P2860
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Survival benefits from neoadju ...... al carcinoma: a meta-analysis.
@en
Survival benefits from neoadju ...... al carcinoma: a meta-analysis.
@nl
type
label
Survival benefits from neoadju ...... al carcinoma: a meta-analysis.
@en
Survival benefits from neoadju ...... al carcinoma: a meta-analysis.
@nl
prefLabel
Survival benefits from neoadju ...... al carcinoma: a meta-analysis.
@en
Survival benefits from neoadju ...... al carcinoma: a meta-analysis.
@nl
P2093
P921
P1433
P1476
Survival benefits from neoadju ...... eal carcinoma: a meta-analysis
@en
P2093
Australasian Gastro-Intestinal Trials Group
Bryan Burmeister
John Simes
John Zalcberg
Kerwyn Foo
Val Gebski
P304
P356
10.1016/S1470-2045(07)70039-6
P577
2007-03-01T00:00:00Z